About Humana Inc
- Industry: Health Care
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.humana.com/
Frequently Asked Questions
What is the 52-week range for HUM?
The 52-week high is $428.8818 and the 52-week low is $163.11.
What is the P/E ratio for HUM?
The Price to Earnings (P/E) ratio is 36.46.
What is the dividend yield for HUM?
The indicated annual dividend yield is 0.68%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 6.92%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 0.88%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.74.
Analyst Recommendation Trends
Wall Street analyst consensus for HUM over the last few months:
Latest HUM News
The Insurance Industry Is Shedding Jobs. It’s Not All About AI.
Insurers are adapting to shifting market conditions with aggressive cost-cutting measures.
UnitedHealth and Humana cutting Medicare Advantage plans in 2027
CVS Health's Aetna and Centene are also shrinking their Medicare Advantage offerings as insurers pull back from less profitable markets
UnitedHealth Trades at $365 as It Shuts Plans for 390,000 Medicare Advantage Members. Here’s What It Signals for 2027
Key Stats for UnitedHealth StockCurrent Price: $365. 20Target Price (Mid): ~$586Street Target: ~$482Potential Total Return: ~61%Annualized IRR: ~12% / yearWhat Happened?UnitedHealth Group (UNH:NYSE) is shutting Medicare Advantage plans that cover about 390,000 people for 2027, a company spokesperson told Bloomberg on October 1.
How Much Downside Is Left In CVS Health Stock?
CVS Health (CVS) stock lost 12.7% in the past month without company news, and peers UnitedHealth, Cigna and Elevance Health fell too. The S&P 500 rose 0.6% over the same month. The shares now trade 22.5% below their 52-week high. How much further could CVS stock fall if the market itself turns down.
Humana Reports Third-Quarter Earnings Nov. 6, in the Middle of Open Enrollment. Members Got Their Plan-Change Letters Weeks Earlier. Wall Street Got the Numbers in July
Humana already told investors in July how many members it plans to drop. What your neighbor with a surviving plan has not figured out yet is how quietly the costs on that plan changed before open enrollment closes Dec. 7.
Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
LOUISVILLE, Ky., October 01, 2026--As Medicare’s Annual Election Period (AEP) begins Oct. 15, Humana is offering 2027 Medicare Advantage plans designed to deliver high-value coverage with affordable monthly premiums. Members will have continued access to the benefits they value most – including $0 cost-sharing on in-network primary care visits and labs plus dental, vision, and hearing coverage. Additional 2027 highlights include:
Humana To Offer 2027 Medicare Advantage Plans With Continued Access To The Benefits, Including $0 Cost-Sharing On In-Network Primary Care Visits And Labs Plus Dental, Vision, And Hearing From October 15
Additional 2027 highlights include:Medicare Advantage plans in approximately 2,600 counties across 45 states and Washington, D.C., representing more than 80% of U.S. counties.Expanded Chronic Condition Special Needs
What Are UNH Stock Investors Betting On?
UnitedHealth (UNH) stock trades at 22.5 times its past year's adjusted earnings, which are normalized net income with stock-based pay added back. That multiple leaves little room for error after three years of shrinking operating margins, sitting near the stock's 10-year median despite fundamentally weaker profitability. But the price looks different against the profit expected for fiscal 2026 and fiscal 2027. So what are UnitedHealth investors betting on.
3 Reasons HUM Has Explosive Upside Potential
What a time it’s been for Humana. In the past six months alone, the company’s stock price has increased by a massive 136%, reaching $391.06 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
UnitedHealth Stock Has Gone Nowhere for Five Years. Its Dividend Has Not
UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time. Whether that something is enough to make UNH worth holding now depends on costs that management has not yet fully tamed.
Humana (HUM) Jumped, But What Is Drawing Fresh Attention Now?
Humana (HUM) moved sharply higher this week after Barclays shifted its rating on the insurer to Overweight from Equalweight, indicating that the shares could outperform sector peers. At around US$397.93, Humana’s recent 4.63% 1 day share price return and 3.21% 30 day share price return build on a strong year to date share price return of 50.46%. However, the 3 year total shareholder return has declined 15.34%, suggesting the latest upgrade is being read as a fresh shift in sentiment rather...
Why Humana (HUM) Stock Is Up Today
Shares of health insurance company Humana (NYSE:HUM) jumped 8% in the afternoon session after Barclays upgraded the stock from Equalweight to Overweight.
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
Top S&P500 movers in Friday's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Humana surges: Barclays bets big on Medicare star ratings rebound
Investing.com -- Humana Inc. (NYSE:HUM) shares rose 6% Friday after Barclays upgraded the health insurer to overweight from equal-weight ahead of the upcoming Medicare Star ratings release.
Humana Jumps 7% on Barclays Upgrade and $515 Target; UnitedHealth Nudges Higher
Barclays just broke its silence on Humana with a conviction call that sent shares surging well past anything the broader health care sector is doing today, raising the question of whether this upgrade signals the start of something bigger or a rally built on a single opinion.
Discover which S&P500 stocks are making waves on Friday.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.
Humana Stock Jumps. Why It Could Be a Big Winner in Next Medicare Star Ratings.
Barclays upgraded Humana stock to Overweight from Neutral and raised its price target to $515 from $407.
This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Analysts upgraded First Financial, 3M, Synopsys, Humana and Stem, raising targets for four while maintaining Stem’s $7 target.
IBM upgrade, SpaceX initiation among today's top calls on Wall Street
IBM upgrade, SpaceX initiation among today's top calls on Wall Street
Wondering what's happening in today's S&P500 pre-market session?
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
Barclays Upgrades Humana to Overweight, Raises Price Target to $515
Barclays analyst Andrew Mok upgrades Humana (NYSE:HUM) from Equal-Weight to Overweight and raises the price target from $407 to $515.
Akamai, Atlas Energy Solutions, People And Other Big Stocks Moving Higher On Friday
U.S. stocks rose Friday; Akamai jumped 8.1% on an $11.6B Anthropic cloud deal, while Atlas Energy, Almonty and others posted strong gains.
What Should CVS Stock Investors Be Watching Now?
If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.
Liberty HealthShare’s Dorsey Morrow Makes the Financial Case for Healthsharing on Becker’s Healthcare Podcast
By Exec Edge Editorial Staff Health insurance premiums have climbed for years. Deductibles have climbed right along with them. Yet a growing number of American households are choosing neither, opting instead for a decades-old alternative, which is not health insurance, built around monthly contributions and community values. “People are clearly paying high premiums now,” Liberty […] The post Liberty HealthShare’s Dorsey Morrow Makes the Financial Case for Healthsharing on Becker’s Healthcare Pod
Did UnitedHealth Name The Fix Before Its Stock Ran?
UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce it has entered into a distribution agreement dated August 25, 2026 (the "Distribution Agreement") with CenterWell Pharmacy, Inc. ("CenterWell") the pharmacy services brand of Humana Inc, a major U.S. health...
Can UNH Stock Keep Growing Earnings While Its Sales Stall?
UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.
Monday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Can Cigna's AI Push Help Rein In Rising Healthcare Costs?
CI is expanding AI across care coordination and specialty pharmacy as it seeks to manage elevated healthcare costs and improve access.
Should You Buy CVS Stock For The Margin Aetna Is Rebuilding?
CVS Health (CVS) keeps a little over a penny of profit from every dollar it takes in. A net margin of 1.2% reads like a verdict on the business. On $415.1 billion of revenue, one point of net margin is worth over $4 billion, and 1.2% is closer to a floor than a peak. Management has been working on it through 2026.
2 Unpopular Stocks That Should Get More Attention and 1 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Can Centene Sustain Its Turnaround Amid Membership Pressure?
CNC's profitability is recovering, but rising margins face a key test as Medicaid membership declines and eligibility reviews continue.
New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patients
LOUISVILLE, Ky., September 17, 2026--A new research study finds an association between pharmacy care coordination services and improved health outcomes for cancer patients.
3 Health Care Stocks Built For Higher Rates
When the Federal Reserve lifts rates and signals they may stay elevated for years, the easy-growth playbook breaks. Cash flows today matter more than promises tomorrow, and investors start to care a lot about balance sheet strength, pricing power and dependable dividends. This article walks through three large cap quality defensive stocks that screen well under those rules and explains how the latest Fed move could affect each one. The three stocks below are a sample of what this quality...
Losing Your Medicare Plan? There’s a Silver Lining.
Americans on Medicare Advantage plans may soon get a breakup letter in the mail: Your insurer is canceling your plan. Humana and other Advantage insurers are sending letters this fall to plan members about 2027 coverage. As insurers look to cut costs, some are discontinuing their Advantage plans.
The One Cost Line UnitedHealth Stock Has Not Caught Up To Yet
UnitedHealth's repair job is going to plan almost everywhere. The exception is the cost of its commercial health plans, where medical costs are running modestly above the 11% the company had been expecting. Medicare costs are coming in below what it planned for 2026, and Medicaid cost trend is in line, though management expects Medicaid margins to stay pressured for 2026. That cost divergence is what a holder should watch.
Humana Community Day 2026 Generates 2.2 Million Meals and Community Investments Nationwide
LOUISVILLE, Ky., September 16, 2026--Humana Inc. (NYSE: HUM) today announced the results of Humana Community Day 2026, the company’s annual nationwide day of service. In its third year, Humana Community Day mobilized more than 18,000 employees across 28 states and Puerto Rico, supported 1,200 nonprofit organizations, and positively impacted 2.25 million lives and community members through volunteer projects focused on food security, neighborhood revitalization, environmental stewardship and soci
Quantum Health Names Dr. Susan Mani as Chief Medical Officer
DUBLIN, Ohio, September 15, 2026--Quantum Health, the industry-leading healthcare navigation company, today announced the appointment of Susan Mani, M.D., as Chief Medical Officer. Dr. Mani will shape Quantum Health's clinical strategy, working to improve healthcare experiences, results and affordability for members and clients.
CalmiGo Selected for CMS’s ACCESS Program to Provide Technology-Supported Chronic Care for Behavioral Health Conditions
NEW YORK, September 15, 2026--CalmiGo, developer of the first and only mental health platform that provides immediate relief and long-term care to users suffering from anxiety, PTSD, and panic attacks, announces today that its platform has been selected for CMS’s ACCESS program, offering technology-supported chronic care for behavioral health conditions. Medicare serves over 70 million patients and created the ACCESS program to expand access to technology-supported chronic care. Fourteen additio
Humana (HUM) Stock Could Trade At A Discount Following Its 54% Rebound
Humana has staged a sharp rebound in 2024, and with the stock closing at US$407.02, the big question is whether that move still lines up with what the business earns. With the share price up 53.9% year to date, a lot of future expectations are already riding on Humana's earnings power. New research on integrated specialty pharmacy and the push toward lower drug costs may support more stable margins and cash flows, provided Humana can keep members engaged in these models. The analysts...
CLOV Stock Hits Over 2-Month High As Humana Deal Buzz Builds Ahead Of Investor Conferences
Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.
CVS Stock Returned $24B In Cash: Why Did It Still Lag The Market?
The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.
Should You Buy UNH Stock Because Its Cash Runs Ahead Of Its Profit?
UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Should You Buy Elevance Health Stock For The Margin It Lost?
Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.
UnitedHealth Reshapes Florida WellMed Operations With TPG Deal
UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.
New Study Links Integrated Specialty Pharmacy Care to Faster Access and Lower Costs
LOUISVILLE, Ky., September 10, 2026--A new peer-reviewed study from Humana Healthcare Research published in Health Affairs Scholar found that Medicare Advantage beneficiaries who used an integrated specialty pharmacy, which coordinates pharmacy services with a beneficiary’s health plan, experienced faster access to specialty medications and lower out-of-pocket pharmacy costs compared with beneficiaries using non-integrated specialty pharmacies. The research suggests that greater coordination bet
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.
Is HealthStream (HSTM) a Better Healthcare Bet Than Humana (HUM) Right Now?
On August 11, Humana Inc. (NYSE:HUM) announced that its Medicaid plan, Humana Healthy Horizons in Indiana, is collaborating with HealthStream, Inc. (NASDAQ:HSTM). The partnership expands access to workforce training for caregivers, aiming to recruit and retain talent in rural and underserved communities. While one provides healthcare coverage and the other builds the software to train […]
Why Is UNH Stock Trading At A Premium With The Slowest Growth?
UnitedHealth (UNH) runs the best operating margin of the three managed care companies in its peer group, and the slowest revenue growth of the three. It also carries a significant valuation premium over its peer, Cigna, trading at more than double its earnings multiple.
Can UnitedHealth's AI Strategy Strengthen Optum Insight's Growth?
UNH is investing nearly $1.5B in AI to expand Optum Insight's software offerings, boost efficiency and unlock new growth opportunities.
Is Humana Stock Outperforming the Dow?
Humana has outperformed the broader Dow Jones index over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.
UnitedHealth Slips 3% as TPG Buys Into Florida WellMed Clinics Ahead of Guidance Reaffirmation
TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Insurers Have Already Told Wall Street Which Advantage Plans Die on December 31. Members Are the Last to Know, and the Letter Isn’t Due Until October 2.
Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a rare legal protection most will never realize they have.
UnitedHealth Stock Rises 39% in 6 Months: Should Investors Still Buy?
UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.
1 High-Flying Stock for Long-Term Investors and 2 Facing Headwinds
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
DaVita (DVA) Has Investors Asking A Fresh Question
DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-30 | HILZINGER KURT J | +238 | $384.9125 | $91,609 |
| 2026-09-01 | Nundy Shantanu | +2,549 | - | - |
| 2026-08-01 | Smith Paul John | +544 | - | - |
| 2026-08-01 | Crawford Frederick John | +544 | - | - |
| 2026-06-30 | HILZINGER KURT J | +233 | $392.32 | $91,411 |
| 2026-05-01 | Field Robert Stuart | +852 | - | - |
| 2026-05-01 | Martin Aaron | +8,206 | - | - |
| 2026-05-01 | Mehta Japan | +9,448 | - | - |
| 2026-05-01 | Dintenfass David | +11,273 | - | - |
| 2026-05-01 | Rechtin James A. | +35,633 | - | - |
| 2026-05-01 | Shetty Sanjay K | +9,945 | - | - |
| 2026-05-01 | O'Hara Michelle A. | +10,485 | - | - |
| 2026-05-01 | Ventura Joseph C | +10,318 | - | - |
| 2026-05-01 | Mellet Celeste | -15,387 | - | - |
| 2026-04-01 | Shetty Sanjay K | -401 | $175.44 | $70,351 |
| 2026-04-01 | Shetty Sanjay K | +887 | - | - |
| 2026-03-31 | Renaudin George II | +25 | $173.39 | $4,335 |
| 2026-03-31 | HILZINGER KURT J | +536 | $170.6605 | $91,474 |
| 2026-02-24 | Renaudin George II | -419 | $177.075 | $74,194 |
| 2026-02-24 | Renaudin George II | +1,035 | - | - |
| 2026-02-24 | Ventura Joseph C | -478 | $177.075 | $84,642 |
| 2026-02-24 | Ventura Joseph C | +1,035 | - | - |
| 2026-02-24 | Felter John-Paul W. | -84 | $177.075 | $14,874 |
| 2026-02-24 | Felter John-Paul W. | +165 | - | - |
| 2026-02-23 | Shetty Sanjay K | +810 | $185.205 | $150,016 |
| 2026-02-23 | Felter John-Paul W. | +5,669 | - | - |
| 2026-02-21 | Dintenfass David | -1,182 | $189.655 | $224,172 |
| 2026-02-21 | Dintenfass David | +3,858 | - | - |
| 2026-02-13 | Mehta Japan | -430 | $181.4575 | $78,027 |
| 2026-02-13 | Mehta Japan | +1,682 | - | - |
| 2026-02-13 | Mellet Celeste | -4,204 | $181.4575 | $762,847 |
| 2026-02-13 | Mellet Celeste | +7,763 | - | - |
| 2026-02-12 | Martin Aaron | +17,031 | - | - |
| 2026-01-08 | Rechtin James A. | -2,183 | - | - |
| 2026-01-08 | Rechtin James A. | -980 | $279.1475 | $273,565 |
| 2026-01-08 | Rechtin James A. | +2,183 | - | - |
| 2026-01-02 | Bono Raquel C. | +766 | - | - |
| 2026-01-02 | Frederick Wayne A.I. | +766 | - | - |
| 2026-01-02 | Klevorn Marcy S | +766 | - | - |
| 2026-01-02 | Garratt John W | +766 | - | - |
| 2026-01-02 | Mesquita Jorge S. | +766 | - | - |
| 2026-01-02 | Feinberg David T | +766 | - | - |
| 2026-01-02 | Smith Gordon | +766 | - | - |
| 2026-01-02 | DAMELIO FRANK A | +766 | - | - |
| 2026-01-02 | HILZINGER KURT J | +766 | - | - |
| 2026-01-02 | KATZ KAREN | +766 | - | - |
| 2026-01-01 | O'Hara Michelle A. | -1,093 | $258.8675 | $282,942 |
| 2026-01-01 | O'Hara Michelle A. | +2,353 | - | - |
| 2025-12-31 | Bono Raquel C. | +34 | $258.8675 | $8,801 |
| 2025-12-31 | Frederick Wayne A.I. | +35 | $258.8675 | $9,060 |
| 2025-12-31 | Klevorn Marcy S | +28 | $258.8675 | $7,248 |
| 2025-12-31 | Garratt John W | +16 | $258.8675 | $4,142 |
| 2025-12-31 | Feinberg David T | +29 | $258.8675 | $7,507 |
| 2025-12-31 | Feinberg David T | +70 | $258.8675 | $18,121 |
| 2025-12-31 | Smith Gordon | +10 | $258.8675 | $2,589 |
| 2025-12-31 | Smith Gordon | +122 | $258.8675 | $31,582 |
| 2025-12-31 | HILZINGER KURT J | +357 | $258.8675 | $92,416 |
| 2025-12-31 | HILZINGER KURT J | +611 | $258.8675 | $158,168 |
| 2025-12-31 | KATZ KAREN | +49 | $258.8675 | $12,685 |
| 2025-12-15 | Mehta Japan | -470 | $270.155 | $126,973 |
| 2025-12-15 | Mehta Japan | +1,194 | - | - |
| 2025-12-15 | Dintenfass David | -918 | $270.155 | $248,002 |
| 2025-12-15 | Dintenfass David | +2,032 | - | - |
| 2025-12-15 | Rechtin James A. | -3,372 | $270.155 | $910,963 |
| 2025-12-15 | Rechtin James A. | +7,707 | - | - |
| 2025-12-15 | Shetty Sanjay K | -308 | - | - |
| 2025-12-15 | Shetty Sanjay K | -139 | $270.155 | $37,552 |
| 2025-12-15 | Shetty Sanjay K | +308 | - | - |
| 2025-12-15 | Shetty Sanjay K | -888 | $270.155 | $239,898 |
| 2025-12-15 | Shetty Sanjay K | +1,968 | - | - |
| 2025-12-15 | Renaudin George II | -360 | - | - |
| 2025-12-15 | Renaudin George II | -142 | $270.155 | $38,362 |
| 2025-12-15 | Renaudin George II | +360 | - | - |
| 2025-12-15 | Renaudin George II | -830 | $270.155 | $224,229 |
| 2025-12-15 | Renaudin George II | +2,106 | - | - |
| 2025-12-15 | Felter John-Paul W. | -115 | - | - |
| 2025-12-15 | Felter John-Paul W. | -53 | $270.155 | $14,318 |
| 2025-12-15 | Felter John-Paul W. | +115 | - | - |
| 2025-12-15 | Felter John-Paul W. | -209 | $270.155 | $56,462 |
| 2025-12-15 | Felter John-Paul W. | +455 | - | - |
| 2025-12-15 | O'Hara Michelle A. | -632 | $270.155 | $170,738 |
| 2025-12-15 | O'Hara Michelle A. | +1,401 | - | - |
| 2025-12-15 | Ventura Joseph C | -360 | - | - |
| 2025-12-15 | Ventura Joseph C | -164 | $270.155 | $44,305 |
| 2025-12-15 | Ventura Joseph C | +360 | - | - |
| 2025-12-15 | Ventura Joseph C | -933 | $270.155 | $252,055 |
| 2025-12-15 | Ventura Joseph C | +2,046 | - | - |
| 2025-12-15 | Mellet Celeste | -1,222 | $270.155 | $330,129 |
| 2025-12-15 | Mellet Celeste | +2,128 | - | - |
| 2025-11-01 | Smith Gordon | +765 | - | - |